<SEC-DOCUMENT>0001564590-20-000868.txt : 20200113
<SEC-HEADER>0001564590-20-000868.hdr.sgml : 20200113
<ACCEPTANCE-DATETIME>20200113071644
ACCESSION NUMBER:		0001564590-20-000868
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20200112
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200113
DATE AS OF CHANGE:		20200113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROCRINE BIOSCIENCES INC
		CENTRAL INDEX KEY:			0000914475
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330525145
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22705
		FILM NUMBER:		20522759

	BUSINESS ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 617-7600

	MAIL ADDRESS:	
		STREET 1:		12780 EL CAMINO REAL
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>nbix-8k_20200112.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-01-13T11:50:45.7636846+00:00 -->
<!-- Version            : 5.0.1.319 -->
<!-- Package ID         : 302c29207996465a944102a321d9abd3 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:nbix="http://www.neurocrine.com/20200112" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
nbix-8k_20200112.htm
</title>
</head>
<!-- NG Converter v5.0.19273.161 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0000914475_20200112_20200112">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:EntityCentralIndexKey" contextRef="C_0000914475_20200112_20200112">0000914475</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="nbix-20200112.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0000914475_20200112_20200112">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0000914475</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-12</xbrli:startDate>
					<xbrli:endDate>2020-01-12</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="border-top:Double 2.25pt;padding-top:1pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<div style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-left:0%;margin-right:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, D.C. 20549 </p></div>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-left:0%;margin-right:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0000914475_20200112_20200112">8-K</ix:nonNumeric> </p></div>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-left:0%;margin-right:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d) of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">the Securities Exchange Act of 1934 </p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0000914475_20200112_20200112" format="ixt:datemonthdayyearen">January 12, 2020</ix:nonNumeric></p></div>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-left:0%;margin-right:0%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000003" name="dei:EntityRegistrantName" contextRef="C_0000914475_20200112_20200112">NEUROCRINE BIOSCIENCES, INC.</ix:nonNumeric> </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as Specified in Its Charter) </p></div>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:34%;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0000914475_20200112_20200112" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityFileNumber" contextRef="C_0000914475_20200112_20200112">0-22705</ix:nonNumeric></p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000008" name="dei:EntityTaxIdentificationNumber" contextRef="C_0000914475_20200112_20200112">33-0525145</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:34%;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction</p>
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of Incorporation)</p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom" style="width:34%;">
<p style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:33%;">
<p style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:33%;">
<p style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:67%;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityAddressAddressLine1" contextRef="C_0000914475_20200112_20200112">12780 El Camino Real</ix:nonNumeric>,</p>
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:EntityAddressCityOrTown" contextRef="C_0000914475_20200112_20200112">San Diego</ix:nonNumeric>, <ix:nonNumeric id="F_000011" name="dei:EntityAddressStateOrProvince" contextRef="C_0000914475_20200112_20200112" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></p>
<p style="line-height:2pt;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000012" name="dei:EntityAddressPostalZipCode" contextRef="C_0000914475_20200112_20200112">92130</ix:nonNumeric></p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="width:67%;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Principal Executive Offices)</p>
<p style="line-height:2pt;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:33%;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:6pt;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s Telephone Number, Including Area Code: (<ix:nonNumeric id="F_000013" name="dei:CityAreaCode" contextRef="C_0000914475_20200112_20200112">858</ix:nonNumeric>) <ix:nonNumeric id="F_000014" name="dei:LocalPhoneNumber" contextRef="C_0000914475_20200112_20200112">617-7600</ix:nonNumeric></p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:34.17%;"></td>
<td style="width:1.02%;"></td>
<td style="width:5.38%;"></td>
<td style="width:24.26%;"></td>
<td style="width:1.02%;"></td>
<td style="width:34.16%;"></td>
</tr>
<tr>
<td colspan="6" valign="middle">
<p style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="middle">
<p style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="middle">
<p style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle">
<p style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle">
<p style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle">
<p style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt; border-bottom:solid 0.75pt transparent;">
<p style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol</p></td>
<td valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt; border-bottom:solid 0.75pt transparent;">
<p style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:Security12bTitle" contextRef="C_0000914475_20200112_20200112">Common Stock, $0.001 par value</ix:nonNumeric></p></td>
<td valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;">
<p style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:TradingSymbol" contextRef="C_0000914475_20200112_20200112">NBIX</ix:nonNumeric></p></td>
<td valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;">
<p style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:1.5pt;padding-Right:1.5pt;padding-Top:1.5pt;padding-Bottom:1.5pt;">
<p style="text-align:center;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:SecurityExchangeName" contextRef="C_0000914475_20200112_20200112" format="ixt-sec:exchnameen">Nasdaq Global Select Market</ix:nonNumeric></p></td>
</tr>
</table></div>
<div style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-left:0%;margin-right:0%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below): </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000015" name="dei:WrittenCommunications" contextRef="C_0000914475_20200112_20200112" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </p></td>
</tr>
<tr>
<td valign="top" style="width:4%;">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:SolicitingMaterial" contextRef="C_0000914475_20200112_20200112" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </p></td>
</tr>
<tr>
<td valign="top" style="width:4%;">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:PreCommencementTenderOffer" contextRef="C_0000914475_20200112_20200112" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </p></td>
</tr>
<tr>
<td valign="top" style="width:4%;">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0pt;;font-size:10pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:PreCommencementIssuerTenderOffer" contextRef="C_0000914475_20200112_20200112" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="width:96%;">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</p></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000005" name="dei:EntityEmergingGrowthCompany" contextRef="C_0000914475_20200112_20200112" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-top:6pt;border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family:Segoe UI Symbol;"><span style="font-size:10pt;font-family:'Times New Roman'">&#9744;</span></span></p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.67%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item </span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.02.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations and Financial Condition.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 12, 2020, Neurocrine Biosciences, Inc. (the &#8220;Company&#8221;), issued a press release announcing preliminary fourth quarter 2019 and full year 2019 net product sales results. The Company&#8217;s financial statements for the fourth quarter 2019 and full year 2019 have not yet been completed and could result in changes to these preliminary net product sales results. The press release also contained certain 2020 expected milestones related to the Company&#8217;s products and product candidates. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with General Instruction B.2 of Form 8-K, the information in this Item 2.02 and Exhibit 99.1 of this Current Report on Form 8-K, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the Exchange Act, except as expressly set forth by specific reference in such a filing.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Special Note Regarding Forward-Looking Statements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Current Report on Form 8-K contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These statements relate to future events and involve known and unknown risks, uncertainties and other factors which may cause the Company&#8217;s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;may&#8221;, &#8220;will&#8221;, &#8220;should&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;expects&#8221;, &#8220;plans&#8221;, &#8220;anticipates&#8221;, &#8220;believes&#8221;, &#8220;estimates&#8221;, &#8220;projects&#8221;, &#8220;predicts&#8221;, &#8220;potential&#8221; and similar expressions intended to identify forward-looking statements. These statements reflect the Company&#8217;s current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent the Company&#8217;s estimates and assumptions only as of the date of this Current Report on Form 8-K.</p>
<div style="border-top:none 0pt;padding-top:0pt;border-bottom:none 0pt;padding-bottom:0pt;border-left:none 0pt;padding-left:0pt;border-right:none 0pt;padding-right:0pt;margin-left:8.67%;margin-right:0%;">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.67%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 9.01.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:0pt;margin-right:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Statements and Exhibits.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:10%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p></td>
<td valign="bottom" style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:89%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:89%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0pt;;color:#0563C1;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="nbix-ex991_29.htm"><span style="text-decoration:underline;">Press Release dated January 12, 2020</span></a></p></td>
</tr>
<tr style="height:4.95pt;">
<td valign="bottom" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="bottom" style="width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr style="height:17.55pt;">
<td valign="bottom" style="width:10%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;margin-right:0pt;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File</p></td>
</tr>
</table></div></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<hr style="page-break-after:always" />
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NEUROCRINE BIOSCIENCES, INC.</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59%; border-bottom:solid 0.75pt transparent;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: January 13, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3%; border-bottom:solid 0.75pt transparent;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%; border-bottom:solid 0.75pt #000000;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Darin M. Lippoldt</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%; border-top:solid 0.75pt #000000;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Darin M. Lippoldt</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59%;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3%;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37%;">
<p style="border-top:none 0pt;border-bottom:none 0pt;border-left:none 0pt;border-right:none 0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Legal Officer</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>nbix-ex991_29.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
nbix-ex991_29.htm
</title>
</head>
<!-- NG Converter v5.0.19273.161 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">FOR IMMEDIATE RELEASE</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-weight:bold;font-size:11.5pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:14pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2019 Net Product Sales Results and 2020 Program Milestones</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:13pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;color:#auto;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:13pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;color:#auto;font-size:13pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;color:#auto;font-size:13pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;color:#auto;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:13pt;"><font style="font-style:italic;color:#000000;">INGREZZA</font><font style="font-style:italic;font-size:12pt;color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></font><font style="font-style:italic;color:#000000;"> (valbenazine) Preliminary Fourth Quarter Net Product Sales of Approximately $238 Million </font><font style="font-style:italic;color:#000000;">with Approximately 42,100 TRx </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:13pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;color:#auto;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:13pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;color:#auto;font-size:13pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;color:#auto;font-size:13pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;color:#auto;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:13pt;"><font style="font-style:italic;color:#000000;">INGREZZA</font><font style="font-style:italic;font-size:12pt;color:#000000;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></font><font style="font-style:italic;color:#000000;"> (valbenazine) Preliminary Full-Year 2019 Net Product Sales of Approximately $753 Million </font><font style="font-style:italic;color:#000000;">with Approximately 132,700 TRx </font><font style="font-style:italic;color:#000000;"> </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SAN DIEGO, Jan. 12, 2020 - Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today provided an update on its business performance, including preliminary net product sales results for 2019, and key commercial and clinical development milestones for 2020. Kevin Gorman, Chief Executive Officer of Neurocrine Biosciences, will discuss these updates as part of a webcast presentation at the 38<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, Jan. 13 at 11:30 a.m. Pacific Time (2:30 p.m. Eastern Time).&nbsp;&nbsp; </p>
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"><a name="_Hlk501551350"></a><a name="_Hlk534372687"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preliminary Fourth Quarter and Full-Year 2019 INGREZZA<font style="font-weight:normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup></font> (valbenazine) Net Product Sales and Financial Results (Unaudited)</p>
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on preliminary unaudited financial information, the Company expects INGREZZA net product sales for the three months and full-year ended December 31, 2019 to be approximately $238 million and $753 million, respectively, compared to $130 million and $410 million for the same periods in 2018. Preliminary analysis of INGREZZA net product sales and TRx for the fourth quarter 2019 compared to third quarter 2019 suggests:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;line-height:14pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;line-height:14pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;line-height:14pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Continued strength in new patient additions</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:14pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:14pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;line-height:14pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">End of fourth quarter days-on-hand channel inventory increased relative to the third quarter due to timing of quarter-end purchases resulting in an approximate $11 million benefit to net product sales. Given the increase to year-end channel inventory, the Company anticipates this may lead to a reduction to channel inventory in the first quarter of 2020. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:0pt;line-height:14pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:0pt;line-height:14pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-top:0pt;line-height:14pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">INGREZZA net product sales per prescription of $5,650 for the fourth quarter of 2019</p></td></tr></table></div>
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preliminary unaudited cash and marketable securities balance as of December 31, 2019 is $970 million.</p>
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;Our results reflect our team&#8217;s dedication to educating healthcare providers and patients about tardive dyskinesia as seen in the growing number of patients receiving treatment with INGREZZA. We still have a lot of work to do as a majority of people suffering from tardive dyskinesia remain undiagnosed and untreated,&#8221; said Kevin Gorman, Ph.D., Chief Executive Officer of Neurocrine Biosciences. &#8220;In 2020, we aim to have three FDA-approved medicines in four indications and will remain focused on helping more tardive dyskinesia patients with INGREZZA, preparing for the anticipated approval of opicapone in the U.S., and advancing our growing pipeline, including three pivotal clinical trial programs. We are well positioned as we evolve towards becoming a leading global neuroscience-focused biopharmaceutical company.&#8221;</p>
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020 INGREZZA Net Product Sales Outlook</font></p>
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the first quarter of 2020, the Company expects INGREZZA net product sales to be impacted as a result of payer-related seasonal dynamics, gross-to-net discount increases from payer and Medicare Part D rebates, and potential reduction in channel inventory. The Company does not intend to provide formal INGREZZA net product sales guidance for 2020 as the tardive dyskinesia market continues to evolve.</p>
<p style="line-height:14pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020 Expected Milestones and Key Activities</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">INGREZZA </font><font style="text-decoration:underline;">(valbenazine)</font><font style="text-decoration:underline;"> for Tardive Dyskinesia</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&#8220;Talk About TD&#8221; disease state awareness campaign</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Continued execution of post-marketing clinical studies, including RE-KINECT, the largest real-world study in patients with possible tardive dyskinesia</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Presentations at key scientific annual meetings, including American Academy of Neurology (AAN), American Psychiatric Association (APA), International Parkinson and Movement Disorder Society (MDS)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Regulatory submissions for approval by Mitsubishi Tanabe in ASEAN territory</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Valbenazine for Chorea in Huntington Disease</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Advance the current Phase III study recruitment and initiate open label portion of study during 1H 2020</p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Elagolix in Collaboration with AbbVie </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Prescription Drug User Fee Act (PDUFA) date in Q2 2020 of elagolix for uterine fibroids</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Continued launch of ORILISSA<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup> (elagolix) to treat moderate to severe pain associated with endometriosis by AbbVie </p></td></tr></table></div>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Opicapone for Parkinson&#8217;s Disease</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">PDUFA date of April 26, 2020</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Preparation for commercial launch</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Presentations at key scientific annual meetings, including AAN, MDS</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Crinecerfont (NBI-74788) for Congenital Adrenal Hyperplasia (CAH) </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Phase IIa data (adults) oral presentation in March at ENDO 2020 </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Global registrational study initiation (adults) in mid-2020</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Advancement of pediatric plan including Phase IIa study</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">NBIb-1817 (VY-AADC) for Parkinson&#8217;s Disease</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Present 3yr follow up data from study PD-1101 at appropriate medical conference</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Implement amended protocol for RESTORE-1 registration trial by mid-year based upon feedback from the U.S. Food and Drug Administration (FDA)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Initiate RESTORE-II registration trial in 2H 2020</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">NBI-921352 (XEN901) for Epilepsy</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">File Investigational New Drug (IND) application with the FDA in mid-2020 in order to start a Phase II trial in SCN8A developmental and epileptic encephalopathy patients in 2H 2020</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="text-decoration:underline;">ACT-709478 </font><font style="text-decoration:underline;">for Epilepsy</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_Hlk29552931"></a>Upon IND application acceptance by the FDA, expected in mid-2020, the Company will have 30 days to exercise the option to license ACT-709478</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</font></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">A Phase II study in a rare pediatric epilepsy is planned in 2H 2020</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About INGREZZA<font style="font-weight:normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">&#174; </sup></font>(valbenazine) Capsules<font style="font-size:11.5pt;"> <br /></font><font style="font-weight:normal;">INGREZZA, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, is the first&#160;FDA-approved product indicated for the treatment of adults with tardive dyskinesia, a condition associated with uncontrollable, abnormal and repetitive movements of the face, torso, and/or other body parts.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INGREZZA is thought to work by reducing the amount of dopamine released in a region of the brain that controls movement and motor function, helping to regulate nerve signaling in adults with tardive dyskinesia. VMAT2 is a protein in the brain that packages neurotransmitters, such as dopamine, for transport and release in presynaptic neurons. INGREZZA, developed in Neurocrine's laboratories, is novel in that it selectively inhibits VMAT2 with no appreciable binding affinity for VMAT1, dopaminergic (including D2), serotonergic, adrenergic, histaminergic, or muscarinic receptors. Additionally, INGREZZA can be taken for the treatment of tardive dyskinesia as one capsule, once-daily, together with psychiatric medications such as antipsychotics or antidepressants.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Important Safety Information</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contraindications&#160;<br /><font style="font-weight:normal;">INGREZZA is contraindicated in patients with a history of hypersensitivity to valbenazine or any components of INGREZZA. Rash, urticaria, and reactions consistent with angioedema (e.g., swelling of the face, lips, and mouth) have been reported.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warnings &amp; Precautions<font style="font-weight:normal;">&#160;<br /></font>Somnolence&#160;&#160;<br /><font style="font-weight:normal;">INGREZZA can cause somnolence. Patients should not perform activities requiring mental alertness such as operating a motor vehicle or operating hazardous machinery until they know how they will be affected by INGREZZA.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">QT Prolongation<font style="font-weight:normal;">&#160;&#160;<br />INGREZZA may prolong the QT interval, although the degree of QT prolongation is not clinically significant at concentrations expected with recommended dosing. INGREZZA should be avoided in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. For patients at increased risk of a prolonged QT interval, assess the QT interval before increasing the dosage.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk14157857"></a>Parkinsonism</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">INGREZZA may cause Parkinsonism in patients with tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors.&nbsp;&nbsp;Reduce the dose or discontinue INGREZZA treatment in patients who develop clinically significant parkinson-like signs or symptoms.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>Adverse Reactions<font style="font-weight:normal;">&#160;<br />The most common adverse reaction (&#8805;5% and twice the rate of placebo) is somnolence. Other </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">adverse reactions (&#8805;2% and &gt;placebo) include: anticholinergic effects, balance disorders/falls, headache, akathisia, vomiting, nausea, and arthralgia.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You are encouraged to report negative side effects of prescription drugs to the&#160;FDA. Visit MedWatch at&#160;<font style="font-weight:bold;text-decoration:underline;">www.fda.gov/medwatch</font>&#160;or call 1-800-FDA-1088.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Please see INGREZZA full Prescribing Information at&#160;<font style="text-decoration:underline;">www.INGREZZA.com/PI</font>. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk5372777"></a>About&#160;Neurocrine Biosciences, Inc.<font style="font-weight:normal;"><br /><a name="_Hlk5372777"></a>Neurocrine Biosciences (Nasdaq: NBIX) is a neuroscience-focused, biopharmaceutical company with more than 25 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders.&#160;The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia and endometriosis* and clinical development programs in multiple therapeutic areas including Parkinson's disease, chorea in Huntington disease, congenital adrenal hyperplasia, epilepsy, uterine fibroids* and polycystic ovary syndrome*.&#160;Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems.&#160;For more information, visit&#160;</font><font style="color:#0000FF;text-decoration:underline;font-weight:normal;">neurocrine.com</font><font style="font-weight:normal;">, and follow&#160;the company on&#160;</font><font style="color:#0000FF;text-decoration:underline;font-weight:normal;">LinkedIn</font><font style="font-weight:normal;">.&#160;(</font><font style="font-style:italic;font-weight:normal;">*in collaboration with AbbVie</font><font style="font-weight:normal;">)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking Statements </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to: our preliminary unaudited financial information; the benefits to be derived from our products and product candidates, including INGREZZA and our partnered product, ORILISSA; the value INGREZZA, ORILISSA, and/or our product candidates may bring to patients; the continued success of the launch of INGREZZA; AbbVie&#8217;s launch of ORILISSA; the opicapone NDA; our financial and operating performance, including our future expenses; our collaborative partnerships; and the timing of completion of our clinical, regulatory, and other development activities and those of our collaboration partners. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are: risks and uncertainties associated with items that may be identified during the financial statement closing process that cause adjustments to the estimates included in this press release; our future financial and operating performance; risks associated with the commercialization of INGREZZA and ORILISSA; risks that the opicapone NDA may not obtain regulatory approval from the&#160;FDA&#160;or such approval may be delayed or conditioned; risks related to the development of our product candidates; risks associated with our dependence on third parties for development and manufacturing activities related to INGREZZA and our product candidates, and our ability to manage these third parties; risks that the FDA or other regulatory authorities may make adverse decisions regarding our products or product candidates; risks associated with our dependence on AbbVie for the commercialization of ORILISSA and the continued development of elagolix;&#160;risks associated with our dependence on BIAL for development and manufacturing activities related to opicapone, and our ability to manage BIAL; risks that clinical development activities may not be completed on time or at all, or may be delayed for regulatory, manufacturing, or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials; risks that the potential </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">benefits of the agreements with our collaboration partners may never be realized; risks that </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our products,</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and/or our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and other risks described in </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> periodic reports filed with the S</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EC</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, including without limitation </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">quarterly report on Form 10-Q for the quarter ended September 30, 2019. Neurocrine disclaims any obligation to update the statements contained in this press release after the date hereof.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">###</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contact: Neurocrine Biosciences, Inc.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Navjot Rai (Media)</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">858-617-7623</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">media@neurocrine.com</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Todd Tushla (Investors)</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">858-617-7143</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#0000FF;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">ir@neurocrine.com</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>nbix-20200112.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-01-13T11:50:45.7636846+00:00 -->
<!-- Version            : 5.0.1.319 -->
<!-- Package ID         : 302c29207996465a944102a321d9abd3 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:nbix="http://www.neurocrine.com/20200112" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.neurocrine.com/20200112" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" namespace="http://xbrl.sec.gov/country/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" namespace="http://xbrl.sec.gov/invest/2013-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" namespace="http://fasb.org/srt/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd" namespace="http://fasb.org/srt-roles/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" namespace="http://fasb.org/srt-types/2019-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" namespace="http://fasb.org/us-gaap/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" namespace="http://fasb.org/us-roles/2019-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" namespace="http://fasb.org/us-types/2019-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.neurocrine.com/20200112/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20200112_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nbix-20200112_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.neurocrine.com/20200112/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>nbix-20200112_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-01-13T11:50:45.7636846+00:00 -->
<!-- Version            : 5.0.1.319 -->
<!-- Package ID         : 302c29207996465a944102a321d9abd3 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of each class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Name of each exchange on which registered</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>nbix-20200112_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2020-01-13T11:50:45.7636846+00:00 -->
<!-- Version            : 5.0.1.319 -->
<!-- Package ID         : 302c29207996465a944102a321d9abd3 -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.neurocrine.com/20200112/role/TemplateLink" xlink:href="nbix-20200112.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.neurocrine.com/20200112/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="nbix-20200112.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.neurocrine.com/20200112/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>nbix-8k_20200112_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nbix-20200112.xsd" xlink:type="simple"/>
    <context id="C_0000914475_20200112_20200112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000914475</identifier>
        </entity>
        <period>
            <startDate>2020-01-12</startDate>
            <endDate>2020-01-12</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="C_0000914475_20200112_20200112" id="F_000001">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="C_0000914475_20200112_20200112" id="F_000004">0000914475</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="C_0000914475_20200112_20200112" id="F_000000">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="C_0000914475_20200112_20200112" id="F_000002">2020-01-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="C_0000914475_20200112_20200112" id="F_000003">NEUROCRINE BIOSCIENCES, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0000914475_20200112_20200112" id="F_000007">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="C_0000914475_20200112_20200112" id="F_000006">0-22705</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="C_0000914475_20200112_20200112" id="F_000008">33-0525145</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0000914475_20200112_20200112" id="F_000009">12780 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="C_0000914475_20200112_20200112" id="F_000010">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0000914475_20200112_20200112" id="F_000011">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0000914475_20200112_20200112" id="F_000012">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0000914475_20200112_20200112" id="F_000013">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0000914475_20200112_20200112" id="F_000014">617-7600</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0000914475_20200112_20200112" id="F_000019">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0000914475_20200112_20200112" id="F_000020">NBIX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0000914475_20200112_20200112" id="F_000021">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications contextRef="C_0000914475_20200112_20200112" id="F_000015">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="C_0000914475_20200112_20200112" id="F_000016">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="C_0000914475_20200112_20200112" id="F_000017">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="C_0000914475_20200112_20200112" id="F_000018">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="C_0000914475_20200112_20200112" id="F_000005">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>10
<FILENAME>0001564590-20-000868-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-20-000868-xbrl.zip
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MI+WP=^MMN=.LR\56\6I<_0=02P,$%     @ %3HM4!@0N8 B!P  ETD  !4
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M2$(C%)K''>>B+% N 68;W(3&U0/'TW/AO5 JD;T1(+F4M*U.&=637%+5'IO
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M<J?K]=-RO7JJG9]5SBZJ9_]=+M?+Y40'_Q,N@"3^U<FI5M9TK:+7$A5OJ?E
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M$HI%<G-+3.KK.Q;M/R_8>:?Y/XU:F(/2GX2.AT8YEYC% )8E,DI!]$T"Z&P
MF@&4300WQ*!E$;JBT**^-;<[/\]+*=S8H)D-?.Y*X4[SKY3"0Y3"$K/8"4 &
M !4WD +X9Z:NHOJ0O%SX&0D$9"-0$@K@"#C26A". XS"R84E-"%N( H_M5\@
MC!G@8]P7=0!?+$XUC&QR?QLOD8B2RN +$%0KQTN XD5?)CCD#/9IL!^!C(B(
MR,C#"Q'KT>-F9C$-*F$!I2=C<JAA$H:%?,("P0DG<2 1'X5$P)_S%L3B+:G!
M]<YF#_.USO^SUZ8+&?M.<=S5UZ;WG7^E3;\X,[#<+':+;P;^'07E/"UC4B2@
M'K[;J;W<:2YRUTA_M/;O&(BNPA*/%M JHA$>-T/RJH'N:V'5LA%>J@$F SD]
M'F!D&2.PL%FSL00P(]_M[^8.?Z.*)#WFEOWP8J_=;AY^2'4>L=>B'P@0.1 D
ME@@>XB6MW4/#?.%+CV<&'(TY)\ Q+*+6+IN@;1C%N43P1T^E #FX]A'F^!-S
MC9D%R7'3C0#$X6S_0*LQCABEQ / #_D0&AA#CO!+\+MX0ED"REUEZJ+!?@&^
M2C#$/^3P%,X"1?'\L=+72+"O\'$<V/ W!;PWH>&%BI$=TWY?:!R\KU4XCU M
M0@Y$II$O^2!2AA(F/OQ-U B_1@O9.@1%)?T;F8KS8>.X\04)BP9SN].-" 35
MV!BF)4.<#$W11N;>'G?JA/9&0%2(>X0TXY*B+H1_LUVSFT))$#>=OO)2%TD<
MBB#&!0@5;..<!<@W8FK1:ZB.8VZ7SFG@ @7Z%H6"5<))JACHB($7L]W^V+AL
MV+00]T<8L$1\"Q1G7!#+6*!LE9-.=LJQ'*D$1LUS1XG&:&=L2QP-L0*RXQ@@
M'HN5+?1&<@PNH1BI@-#V&*8)"DAXBK U)ZR*OPT"!6H)#!!LB]N->K96/:GB
M(8>=]41*L7,;#8PF#<<"RZ>@2N.3@IFEX'$>B37Q.GMHS >BW@/IN*[S/ICB
M QZ,P2,ZO &BJ_+VE;!.3[&N1>:O<]+]\/$]-\D%9AS CSP'YGJ#O$7?M%VF
M<%%F[$^EFC+Q.8:=395]2)- J>L2?E\N9;'*:.8XU=9(+ @CW#L'9A-9$J[W
M$FL_N,-)%IQ,A*Y3^ 8#PH(;?)T(K":PK?1,#2V9,;!.=1P9"P\4 (8\M&(L
MVJ!1R R>$L "NW6.I0C'\*0>QE*LC8Q5 @N,9JZ(HX AG8FC--A5:8Z^@L=$
M"A^:8 0')N0P&J/,8'#;[ >I] F;9S48N  4H9K%!Q;<@RVT\7%:.FMHEQ"Q
MKXP*I$4_(3X%#BM>W2".^+>8L ZF3,F1>HPI_OF+N@11'+K/!Q"H"24?I&AB
MD$G+L8AY=7"WW3A5,''?FTG>KIR,'><R-F4RGD'$\U[O-:Q^@/,STUT"25BU
M>.9R,I#UV:]X<,TZ%/>X.LZ" P !**=B$DS+</ _!558>ARL-<STV2<YEG/'
M*I&O1/YQBD*$C>[9S$2L3%*WN!B]DCQ899+4EPCKB[#6Q4G]W]VSDZ,KZZ$$
M,#5 >H#T>5 ?*QWX=!/E2*<#<? ,(U$'S$+R2IE4RJ12)BNG3,Y++QT8K.O'
M=R8H")U033^WKPV$@K3*E!;IA$*#AHG *^2^""=Y:B%0@PE;[W3.-FK%1>=F
MX@TE3^ OUC%&>=+F=M8[YYT-?&4$7Q7@]H@4C$B 6C&N O=4C01E8(ZE(=EG
MEW"[2. AI\>7&\]>\]SK%;O5USR?F6ZE>>ZM>9:2@2[$( TXU6*9M!=*0!:H
M@C 8D>?Q>A-V*A/X6IJA9%<\XCW*YW4N3SIG##2&ECC 4[WX]TT&J7XN0DVT
M64=#!< 1=^5=BL!TD(#:/K:N9Q5#6FE-7&' ;P(#=J@>0I OZ*5:(]0ZQSI?
MUNUVG2NHA:=3:0MA$).!<YE(>GTW%A%XD#V!I0\Z<T;M3;Y-D+7>43KG?EIZ
ML<UZ^"D@WZ3>/@GX0 7R$VKJ(U27/7>5=>T[O=[/4K!*8U<:N]+8R\Y Y^6J
MY&.=#MA' V[Q6R$P1<O6SX\_ONUL,#I? <3]I[;-IX-B%ID60.B6)H*J /NR
MIY7TO^5WR"IM4&F#5=4&14(@X&GD#5'./UQTWW<O+SN/>#H#6\^4QP:](H:E
MR"Q4(,>H9N 3(V (P6*L]>4NQ"=\"R]$Y*M0)%HJ?"<>_/H<;U2@\ E!X8>\
M2AKM01YVS8OP*S^^L@.5'5@1!B+49T$?G=VF9<#:+VMW<+XKD:Y$NA+I)62@
M<WK?R89IT$*73K.S6._9R_52YJZJY.?JR/52,M!#RBXZ9S5V>GQ9)3W_1#_I
M".-D'IY,"M>OG[WIUG>W=_?V-FP&5$4#$>'AM*SC:X$%+.\FL=!QP/%=E?6C
MSKN-*K"^VGJYPEO?!MYR:4^.;A2(+O?QD((-!CHAF#Z@5T;LE&MOB,K[Y.SX
M@XVP/WLXMI2[5HE])?8/8J ?[0D,6@RD2716A9H5P5.E ]6J9NH A#^4?OV;
M"*PL)7ZN'+#5D?BE9"!7\T3U3'0RC^]JTP&T1R5OJP $I TJI^M/=+K S>K5
M6WNM7;;^\Z_U3N?X:*-*4SVYK:S UNJHWJ5D(!?[8EL3#>(<!&K,TMCZ6W1"
MB85=Y\?U5JO90O>*7@>(-96;THEC= I6UK#DV0.PI=S$2@M46N!AYZZ&<6#A
M%P]M8P\0\D2!3)&-OSBYO/IP<5)O33EE[N2]WH3<+VH*TJ-#K=,8$V1"^#WN
M7;MC%=V9?^RM4O;X1"J4[/@A>'3Y@.MOCSO5&X3/3(54/MPWX<-ULW=0,F71
M[<[3%MB>YTO>0*F\MX=Z;_7]=FMKI\W6_W-RMM]L6>_M)):!B,VD<M966L=6
M,.V;@&EO05A9-QH)D\A!%AC'ZPE,K7?/CC?0/PNRH[JIV!NA%^"J<I@<?[=G
M-V"A>((G3O(\N%8HZLNCL[U.N3>G:]LI2&DDTF/H\L5##E_S9#@ISJ=9'2U?
M'8S\+1Z,O$HF_JXG(6_-.0GY-DC0.;JJ[S;WMW?W[GW"984<*N10(8=50@Y3
MG93;^SL[[?VMEE48'S%: ]!A"CEP#PQ[0@<1]"89A*BY8[.%7P83TP=KC_,F
M'%M-:H-&AT%_PC)I8P\U4''61@2>)B+XM-!$5>SG>6F7*O;S3<1^.H7SD)]5
MR9FFKD!Y+E\XP(!=G3"O'UDULNQ^PAON70^T OB#RD+I@Q=OZ;_5@>+V).(_
MN8<\FVHB/]U#_@@4;1H(LT@06XT=V@_VJJ?9YNMYZ'0NX45G(LZ,"&Q+<0;>
MLO32@&OL8ZY@?2.P0[AP>$(.MNUFZS^?=J[:6$A&/HO2->31O),$3.AE\W"J
MU5+6*\$U6,*^ZUG']+Q#E>HS6Z'FW/"90UJ13$]%MF7PS#O::83]%#2=#1,(
MN+9GYTD>N!:Q2"1-+W3G,5(+-:(95#+89*6-HNX1FT"9@B\TF$D??72=F,;\
M%B2/R^O?BH>6-PH@IE$IC(OHAGJ/]2:V94?6FH2'U 8$MLI7L>5%#9Q*:3.K
M-,7 G=J$E_<TIX99W';7 &XP^8;;OGH*-IKU@5F0B6IY*R]XOK9'^@D6"0U\
M8D! 04I=D]A;&;/!2"!P/IP2@4+F;=I*%('MOP8/U-A>6;16H4Q I$R-F12+
ML4T^RYH5D$SL'!/3Q.E@8RW,).(44Z+1(M,H-1IS(2B[1D7#M+\9Y@Y.4MH>
MJHS]3D;4$<62*)-"$0233,"-FQ]-/U)4TB! ]@A*HDAC0[!^'VM-)T0W7MZJ
MY9,!/O38>E&6=MS>@!D+S)C:+T'N\-43]_M0FB2_K\9@O# U'C9.@V&PMUV,
MPMI@'=<]G ?!I%;T9L'S6GMXR/.UB.:KF?G-]? < <]J6G@HMC'SN<21$S40
MI _L*=*EHV!#4?2+RW806[K1-0HVQR#U^(DO<,L,_&IN]GBI3/07J) 0I0(^
M8Y>\CV?I=B-JT8-;L;PZ>O77'0]K0866L[VU]0YWW!EPH.+QRD-9335]7#LG
M18 GK(+(#O&5- />KZ0>/A-4V"6,9,5L0NT%@7QGW8MVEQ?<#&LL)?"E"4F0
M/N6>E5V@Q<"S\CZ9/ *C(GP1<K8N&H,&:"MLC^B:BA>@(0!)KSF[DB;##>O(
M][!+)R .A$O^\B.'U>?*7[B.\$53]@,/XT-V#C:"4V>!.8CY)DM.,;#=JDL5
M1BK 5(W]\@MY'.T0T($M3/(!&^P\XW$#R"?PJ=]8C*]FZI#QO$$5L,_OJ:3S
M)[,\4@"N S5 R0P-V'=MF\IR!VM&8BB]@(2A^'+(_P!SIU+L, ^&"ZPJ-AQ.
M9(!\/&'7D1JS(?Q/?U$T"HPG6',;MP(\EDM1Q<E?G9-_NL(.B(&*;+;RKNQ;
MYM"<_T(^03"*@Y'*@K&QL9T&M0DZ*[#(F[[QQ0 [Q8)J@VOBTO,M0$SR=AP
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M<YB$ ?SR_U!+ 0(4 Q0    ( !4Z+5"X.AM^S@0  (87   1
M  "  0    !N8FEX+3(P,C P,3$R+GAS9%!+ 0(4 Q0    ( !4Z+5 8$+F
M(@<  )=)   5              "  ?T$  !N8FEX+3(P,C P,3$R7VQA8BYX
M;6Q02P$"% ,4    "  5.BU0AF>#K/L$  #B*P  %0              @ %2
M#   ;F)I>"TR,#(P,#$Q,E]P<F4N>&UL4$L! A0#%     @ %3HM4*5/9N8;
M%0  H-(  !0              ( !@!$  &YB:7@M.&M?,C R,# Q,3(N:'1M
M4$L! A0#%     @ %3HM4-4<>$T$'   -MH  !$              ( !S28
H &YB:7@M97@Y.3%?,CDN:'1M4$L%!@     %  4 1@$   !#      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6645240032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 12, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan. 12,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NEUROCRINE BIOSCIENCES, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000914475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-22705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0525145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12780 El Camino Real<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">617-7600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NBIX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>12
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nbix-8k_20200112.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "nbix-8k_20200112.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nbix-20200112_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nbix-20200112_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "nbix-20200112.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "https://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 97,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "nbix",
   "nsuri": "http://www.neurocrine.com/20200112",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-8k_20200112.htm",
      "contextRef": "C_0000914475_20200112_20200112",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document And Entity Information",
     "role": "http://www.neurocrine.com/20200112/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nbix-8k_20200112.htm",
      "contextRef": "C_0000914475_20200112_20200112",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of each class"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Name of each exchange on which registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.neurocrine.com/20200112/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3.a.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>97</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="nbix-8k_20200112.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.neurocrine.com/20200112/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="nbix-8k_20200112.htm">nbix-8k_20200112.htm</File>
    <File>nbix-20200112.xsd</File>
    <File>nbix-20200112_lab.xml</File>
    <File>nbix-20200112_pre.xml</File>
    <File>nbix-ex991_29.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+""
MWTG] E!+ P04    "  5.BU0//\E6>X    K @  $0   &1O8U!R;W!S+V-O
M<F4N>&ULS9+!:L,P#(9?9?B>R$Z@&R;UI:.G#@8K;.QF;+4UBQ-C:R1]^SE9
MFS*V!]C1TN]/GT"-"=+T$9]C'S"2PW0W^K9+TH0U.Q$%"9#,";U.94YTN7GH
MH]>4G_$(09L/?42H.%^!1])6DX8)6(2%R%1CC301-?7Q@K=FP8?/V,XP:P!;
M]-A1 E$*8&J:&,YCV\ -,,$(HT_?!;0+<:[^B9T[P"[),;DE-0Q#.=1S+N\@
MX.UI]S*O6[@ND>X,YE_)23H'7+/KY-=Z\[C?,E7QBA=<%*+>\WLI5K)Z>)]<
M?_C=A'UOW<']8^.KH&K@UUVH+U!+ P04    "  5.BU0F5R<(Q &  "<)P
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MP^]&#/?&<0*Z37+",PQP>,D91N1^PU!)4^.@%R^\+_^B%GX'YG\!4$L#!!0
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M @  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSK9)!"H,P$ "_(GE
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M+GAM;%!+ 0(4 Q0    ( !4Z+5 \_R59[@   "L"   1              "
M 9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( !4Z+5"97)PC$ 8
M )PG   3              "  ;8"  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ %3HM4&)W'TJA @  DPL  !@              ( !]P@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( !4Z+5 EUWC+9 (
M  T&   4              "  <X+  !X;"]S:&%R9613=')I;F=S+GAM;%!+
M 0(4 Q0    ( !4Z+5"ZH3F*UP$  #(&   -              "  60.  !X
M;"]S='EL97,N>&UL4$L! A0#%     @ %3HM4##_Y')$ 0  / (   \
M         ( !9A   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( !4Z+5#_
MP"8(O0   (4"   :              "  =<1  !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( !4Z+5 +C]@#(0$  %<$   3
M      "  <P2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     *  H @ (
' !X4      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
